Trial Profile
An Open-label Study of the Tolerability of a Subcutaneous Needle-free Injection Device Used to Administer Fuzeon, Compared With the Standard Needle/Syringe Supplied With Commercial Fuzeon in HIV-1 Infected, ARV Treatment-experienced Adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2014
Price :
$35
*
At a glance
- Drugs Enfuvirtide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms WAND
- Sponsors Roche
- 25 Apr 2008 Status change
- 25 Apr 2008 New trial record.